Want to see IN:NGLFINE full AI Analyst Report?
Top Page
NGL Fine-Chem Ltd.
(NGLFINE)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹2,756.00
▼(-13.74% Downside)
Action:Reiterated
Date:09/13/26
The score is primarily held back by weak cash-flow quality (persistently negative free cash flow and low cash conversion) and currently bearish technical signals (price below key moving averages with negative MACD). Offsetting these, the company shows strong 2026 revenue growth and improved profitability with manageable leverage, and the high dividend yield provides valuation support despite a relatively elevated P/E.
Positive Factors
Revenue re-acceleration
Revenue growth re-accelerated materially in 2026 after a stagnant prior year, indicating improving demand for the company’s products. Sustained top-line expansion can support operating scale, strengthen customer relationships, and provide a foundation for rebuilding profitability over the coming quarters.
Negative Factors
Weak cash generation
Profit conversion into cash remains weak, with operating cash flow representing only a fraction of reported net income and free cash flow negative across the latest three years. Persistent cash shortfalls can constrain internally funded investment and reduce flexibility during expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue re-acceleration
Revenue growth re-accelerated materially in 2026 after a stagnant prior year, indicating improving demand for the company’s products. Sustained top-line expansion can support operating scale, strengthen customer relationships, and provide a foundation for rebuilding profitability over the coming quarters.
Read all positive factors
NGL Fine-Chem Ltd. (NGLFINE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹18.00B
Dividend Yield0.06%
Average Volume (3M)1.15K
Price to Earnings (P/E)31.4
Beta (1Y)1.14
Revenue Growth40.45%
EPS Growth174.03%
CountryIN
Employees502
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)92.59
Shares Outstanding6,178,024
10 Day Avg. Volume646
30 Day Avg. Volume1,151
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.86
Price to Sales (P/S)2.54
P/FCF Ratio-25.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NGL Fine-Chem Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensi...
How the Company Makes Money
NGL Fine-Chem Ltd. primarily makes money by selling manufactured chemical and pharmaceutical products to business customers (B2B). Key revenue streams generally include: (1) Sale of APIs: Revenue is generated from producing and supplying active ph...
NGL Fine-Chem Ltd. Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.36B | 5.01B | 3.68B | 3.39B | 2.78B | 3.18B |
| Gross Profit | 2.19B | 1.76B | 1.86B | 1.70B | 1.38B | 1.66B |
| EBITDA | 932.93M | 874.18M | 338.69M | 678.69M | 404.87M | 788.78M |
| Net Income | 571.99M | 481.27M | 211.24M | 413.17M | 204.96M | 498.97M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.45B | 4.33B | 3.56B | 2.87B | 2.77B |
| Cash, Cash Equivalents and Short-Term Investments | 442.99M | 442.99M | 655.28M | 553.14M | 525.02M | 295.49M |
| Total Debt | 0.00 | 1.09B | 731.53M | 340.04M | 324.99M | 300.01M |
| Total Liabilities | -3.29B | 2.16B | 1.51B | 929.04M | 645.30M | 737.10M |
| Stockholders Equity | 3.29B | 3.29B | 2.82B | 2.63B | 2.23B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | -82.44M | -503.10M | -949.49M | -80.59M | 38.80M | -425.52M |
| Operating Cash Flow | 167.72M | 395.40M | 358.22M | 204.65M | 352.86M | 138.25M |
| Investing Cash Flow | -143.73M | -712.79M | -345.53M | -268.17M | -270.20M | -142.03M |
| Financing Cash Flow | -10.81M | 340.13M | -10.81M | -10.81M | -10.81M | -10.81M |
NGL Fine-Chem Ltd. Technical Analysis
Positive
3194.85
Price Trends
3025.56
Negative
2921.10
Negative
2420.99
Positive
Market Momentum
-41.25
Negative
53.41
Neutral
87.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NGLFINE, the sentiment is Positive. The current price of 3194.85 is above the 20-day moving average (MA) of 2772.11, above the 50-day MA of 3025.56, and above the 200-day MA of 2420.99, indicating a neutral trend. The MACD of -41.25 indicates Negative momentum. The RSI at 53.41 is Neutral, neither overbought nor oversold. The STOCH value of 87.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NGLFINE.
NGL Fine-Chem Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹152.67B | 29.53 | ― | 0.27% | 19.59% | 47.58% | |
65 Neutral | ₹481.07B | 42.58 | ― | 0.69% | 17.57% | 46.53% | |
63 Neutral | ₹44.47B | 42.26 | ― | 0.08% | 10.25% | 33.78% | |
57 Neutral | ₹18.00B | 31.39 | ― | 0.06% | 40.45% | 174.03% | |
56 Neutral | ₹13.75B | 55.03 | ― | 1.05% | 11.96% | -28.48% | |
56 Neutral | ₹62.45B | 47.62 | ― | ― | 51.74% | 77.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:NGLFINE
NGL Fine-Chem Ltd.
2,914.35
1,517.09
108.58%
IN:GLAND
Gland Pharma Ltd.
2,915.40
919.10
46.04%
IN:KOPRAN
Kopran Limited
284.85
116.65
69.36%
IN:MARKSANS
Marksans Pharma Limited
336.90
171.11
103.21%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
474.85
231.06
94.78%
IN:SENORES
Senores Pharmaceuticals Ltd.
1,356.00
662.05
95.40%
NGL Fine-Chem Ltd. Corporate Events
NGL Fine-Chem Sets August 25 Virtual AGM With E-Voting for Shareholders
Aug 4, 2026
NGL Fine-Chem Ltd. has announced that its 45th Annual General Meeting will be held on August 25, 2026 via video conferencing and other audio-visual means, with details on book closure and remote e-voting published in English and Marathi newspapers...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.